THE ROLE OF OMENTAL TRANSFER IN BUERGER'S DISEASE: NEW DELHI'S EXPERIENCE
Australian and New Zealand Journal of Surgery,
Год журнала:
1996,
Номер
66(6), С. 372 - 376
Опубликована: Июнь 1, 1996
Buerger's
disease
is
a
specific,
idiopathic,
recurrent,
segmental,
inflammatory,
obliterative
vascular
involving
medium-sized
arteries
and
veins
of
the
limbs.
We
performed
omental
transfer
on
group
patients
with
that
had
previously
undergone
lumbar
sympathectomy
results
are
described.Between
January
1988
December
1993,
100
cases
peripheral
(PVD)
diagnosed
as
Disease
were
subjected
to
femoral
angiography.
Fifty
angiographic
intermediate/distal
type
blocks
underwent
transposition.Of
50
all
intermittent
claudication,
40
rest
pain
whom
36
non-healing
ulcers,
8
gangrene
32
bilateral
lower
limb
involvement.
Fifteen
posterior
tibial
artery
biopsy
was
in
40.
All
showed
improved
skin
temperature,
decreased
claudication
distance
increased
48.
Ulcers
healed
line
demarcation
receded
six
eight
gangrene.Omental
muscle
microcirculation
forestalled
need
for
amputation
by
providing
symptomatic
relief
clinically
arresting
progress
disease.
Omental
should
be
considered
seriously
an
alternative
other
modalities
therapy
delay
ischaemic
complications
Язык: Английский
Mesenchymal stromal cell therapy (REGENACIP®), a promising treatment option in chronic limb threatening ischemia – a narrative review
Stem Cell Research & Therapy,
Год журнала:
2024,
Номер
15(1)
Опубликована: Окт. 8, 2024
Chronic
Limb
Threatening
Ischemia
(CLTI)
is
a
challenging
clinical
problem
associated
with
high
morbidity
and
mortality.
Endovascular
interventions
have
been
the
cornerstone
of
treatment
whenever
possible.
It
estimated
that
CLTI
represents
<
10%
all
Peripheral
Artery
Disease
patients,
yet
50%
patients
end
up
either
major
amputation
lower
limbs
or
die
cardiovascular
causes
within
one
year
period,
especially
in
those
unsuccessful
revascularization
"no-option"
CLTI.
Cell-based
therapeutics,
bone
marrow-derived
mesenchymal
stromal
cells
emerged
as
potential,
promising,
novel
alternate
therapeutic
modality
management
CLTI,
bolstered
positive
results
numerous
research,
including
randomized
nonrandomized
trials.
REGENACIP
Язык: Английский